CT引导在线自适应立体定向体部放疗治疗胰腺导管腺癌:剂量学与初步临床经验
单中心回顾性分析21例不可切除或局部复发胰腺导管腺癌患者共105次分次,采用Ethos平台CT引导在线自适应放疗,全部患者40 Gy/5次。自适应计划较计划计划显著降低危及器官剂量并提高PTV覆盖,总治疗时间平均29分16秒,仅1例出现放射性相关急性3级以上毒性、1例晚期3级以上毒性。
要点
- 21例不可切除或局部复发PDAC患者接受40 Gy/5次在线自适应SBRT,共105次分次。
- 自适应计划较计划计划显著降低危及器官剂量,同时PTV覆盖更优。
- 平均总治疗时间29分16秒,仅1例急性、1例晚期3级以上放射性相关毒性。
核心结论
- 每日CT引导在线自适应放疗与危及器官剂量显著降低相关,同时获得更优的PTV覆盖。
- 鉴于总治疗时间相对较短,放疗总体耐受良好且易于纳入临床工作流程。
- 作者的初步临床经验表明,在线自适应放疗使PDAC治疗中的安全剂量提升成为可能。
研究设计与样本
- 单中心回顾性分析,纳入21例不可切除或局部复发胰腺导管腺癌患者,共105次分次。
- 全部患者在Ethos平台接受在线自适应放疗,处方剂量40 Gy/5次。
- 与胃、十二指肠和肠管5 mm计划风险体积外扩重叠的PTV接受25 Gy。
- 每次分次先行锥形束CT,AI辅助重新勾画PTV和危及器官,计算并QA自适应计划后与计划计划比较,第二次锥形束CT后实施所选计划。
- 统计分析采用双侧T检验,α为0.05。
主要发现
- 平均总治疗时间为29分16秒(范围16:36–49:40),平均医生主动时间为19分41秒(范围9:25–39:34)。
- 全部105次分次均采用自适应计划治疗。
- 97%的自适应计划达到PTV_4000 V95.0%>95.0%的覆盖目标,100%的自适应计划满足危及器官剂量约束。
- 中位随访6.6个月,仅1例患者出现直接归因于放疗的急性3级以上毒性,仅1例出现直接归因于放疗的晚期3级以上毒性。
关键数值与推荐
- 处方剂量为40 Gy/5次,与胃、十二指肠和肠管5 mm计划风险体积外扩重叠的PTV接受25 Gy。
- PTV_4000 V95.0%覆盖目标为>95.0%,97%的自适应计划达到该目标。
- 100%的自适应计划满足危及器官剂量约束。
- 毒性按CTCAEv5.0记录,急性与晚期3级以上放射性相关毒性各1例。
临床怎么用
- 原文结论指出每日CT引导在线自适应放疗与危及器官剂量显著降低相关并实现更优PTV覆盖。
- 原文结论指出放疗总体耐受良好且易于纳入临床工作流程。
- 作者认为在线自适应放疗使PDAC治疗中的安全剂量提升成为可能。
局限性
- 原文为单中心回顾性分析。
- 中位随访6.6个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE/OBJECTIVES: Retrospective analysis suggests that dose escalation to a biologically effective dose of more than 70 Gy may improve overall survival in patients with pancreatic ductal adenocarcinoma (PDAC), but such treatments in practice are limited by proximity of organs at risk (OARs). We hypothesized that CT-guided online adaptive radiotherapy (OART) can account for interfraction movement of OARs and allow for safe delivery of ablative doses. MATERIALS/METHODS: This is a single institution retrospective analysis of patients with PDAC treated with OART on the Ethos platform (Varian Medical Systems, a Siemens Healthineers Company, Palo Alto). All patients were treated to 40 Gy in 5 fractions. PTV overlapping with a 5 mm planning risk volume expansion on the stomach, duodenum and bowel received 25 Gy. Initial treatment plans were created conventionally. For each fraction, PTV and OAR volumes were recontoured with AI assistance after initial cone beam CT (CBCT). The adapted plan was calculated, underwent QA, and then compared to the scheduled plan. A second CBCT was obtained prior to delivery of the selected plan. Total treatment time (first CBCT to end of radiation delivery) and active physician time (first to second CBCT) were recorded. PTV_4000 V95 %, PTV_2500 V9 5%, and D0.03 cc to stomach, duodenum and bowel were reported for scheduled (S) and adapted (A) plans. CTCAEv5.0 toxicities were recorded. Statistical analysis was performed using a two-sided T test and α of 0.05. RESULTS: 21 patients with unresectable or locally-recurrent PDAC were analyzed, with a total of 105 fractions. Average total time was 29 min and 16 s (16:36-49:40) and average active physician time was 19:41 min (9:25-39:34). All fractions were treated with adapted plans. 97 % of adapted plans met PTV_4000 V95.0 % >95.0 % coverage goal and 100 % of adapted plans met OAR dose constraints. Median follow up was 6.6 months. Only 1 patient experienced acute grade 3+ toxicity directly attributable to radiation. Only 1 patient experienced late grade 3+ toxicity directly attributable to radiation. CONCLUSIONS: Daily CT-based OART was associated with significantly reduced dose OARs while achieving superior PTV coverage. Given the relatively quick total treatment time, radiation delivery was generally well tolerated and easily incorporated into the clinic workflow. Our initial clinical experience demonstrates OART allows for safe dose escalation in the treatment of PDAC.
引用
- Lee A, Pasetsky J, Lavrova E, et al. CT-guided online adaptive stereotactic body radiotherapy for pancreas ductal adenocarcinoma: Dosimetric and initial clinical experience. Clin Transl Radiat Oncol. 2024. PMID: 39149753. doi:10.1016/j.ctro.2024.100813
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。